

Activité antimicrobienne et immuno-modulante de la propolis rouge du Brésil



► Dr Lilian Ceballos, pharmacologue, Pradelles-Cabardès

BIBLIOGRAPHIE

- [1] Kurek-Górecka A et al. 2022. Comparison of the antioxidant activity of propolis samples from different geographical regions. *Plants*, 11(9) : 1203.
- [2] Silva NBS et al. 2024. Antimicrobial aspects of Brazilian red propolis and its compounds. In : *Emerging Paradigms for Antibiotic-Resistant Infections: Beyond the Pill*. Editeurs : Gangwar M, Nath G
- [3] WHO. 2019. New report calls for urgent action to avert antimicrobial resistance crisis.
- [4] Ccana-Ccapatinta GV et al. 2020. *Dalbergia ecastaphyllum* and *Symphonia globulifera* : the botanical sources of isoflavonoids and benzophenones in brazilian red propolis. *Molecules*, 25(9) : 2060.
- [5] Franchin M et al. 2016. Neovestitol, an isoflavonoid isolated from Brazilian red propolis, reduces acute and chronic inflammation: Involvement of nitric oxide and IL-6. *Scientific Reports*, 6 : 36401.
- [6] Sena-Lopes A et al. 2018. Chemical composition, immunostimulatory, cytotoxic and antiparasitic activities of the essential oil from Brazilian red propolis. *PLoS ONE*, 13(2): e0191797.
- [7] da Silva RO et al. 2015. Acute and sub-acute oral toxicity of Brazilian red propolis in rats. *J Ethnopharmacol.*, 170 : 66-71.
- [8] Bueno-Silva B et al. 2013. Anti-Inflammatory and Antimicrobial Evaluation of Neovestitol and Vestitol Isolated from Brazilian Red Propolis. *J. Agric. Food Chem.*, 61 : 4546-4550
- [9] Rufatto LC et al. 2018. Brazilian red propolis: Chemical composition and antibacterial activity determined using bioguided fractionation. *Microbiological research*, 214 : 74-82.
- [10] Santiago MB et al. 2024. The Antibacterial Potential of Brazilian Red Propolis against the Formation and Eradication of Biofilm of *Helicobacter pylori*. *Antibiotics*, 13 : 719.
- [11] Botteon CEA et al. 2021. Biosynthesis and characterization of gold nanoparticles using Brazilian red propolis and evaluation of its antimicrobial and anticancer activities. *Scientific Reports*, 11(1), 1974.
- [12] Fei Wang et al. 2023. Antibacterial and antibiofilm activities of Chinese propolis essential oil microemulsion against *Streptococcus mutans*. *Journal of Applied Microbiology*, 134(3) : 1xad056
- [13] Barreto GdA et al. 2022. Evaluation of the Potential of Brazilian Red Propolis Extracts: An Analysis of the Chemical Composition and Biological Properties. *Applied Sciences* 12(22):11741.
- [14] Costa CL et al. 2021. Inhibitory effect of Brazilian red propolis on planktonic and biofilm forms of *Clostridioides difficile*. *Anaerobe*, 69 : 102322.
- [15] Lotif MAL et al. 2022. A double-blind randomized clinical trial of Brazilian red propolis dentifrice efficacy in orthodontic patients. *J Oral Sci.*, 64(1) : 28-32.
- [16] Hossain et al. 2022. Propolis: An update on its chemistry and pharmacological applications. *Chin Med.*, 17(1) : 100.
- [17] Goletti D et al. 2025. Insights from the 2024 WHO global tuberculosis report—more comprehensive action, innovation, and investments required for achieving WHO end TB goals. *Int. J. Infect. Dis.*, 150 : 107325.
- [18] Holzheimer M et al. 2021. Chemical synthesis of cell wall constituents of *Mycobacterium tuberculosis*. *Chem. Rev.*, 121 : 9554-9643.
- [19] Huang L et al. 2020. "Mycobacterium tuberculosis: Bacterial fitness within the host macrophage," in *Bacteria and Intracellularly*, 127-138. Editors P. Cossart, C. R. Roy, and P. Sansonetti (Hoboken, NJ, USA: John Wiley and Sons, Inc).
- [20] Chakraborty P et al. 2021. Biofilm formation in the lung contributes to virulence and drug tolerance of *Mycobacterium tuberculosis*. *Nat. Commun.*, 12 : 1606.
- [21] Freires IA et al. 2016. A pharmacological perspective on the use of Brazilian red propolis and its isolated compounds against human diseases. *Eur. J. Med. Chem.*, 110 : 267-279.
- [22] Silva NBS et al. 2022. Potential in vitro anti-periodontopathogenic, anti-chikungunya activities and in vivo toxicity of Brazilian red propolis. *Sci. Rep.*, 12 : 21165.
- [23] Silva NBS et al. 2024. Brazilian red propolis reduces the adhesion of oral biofilm cells and the *Toxoplasma gondii* intracellular proliferation. *Biomed. and Pharmacother.*, 181 : 117627.
- [24] Almuhayawi MS. 2020. Propolis as a novel antibacterial agent. *Saudi J. Biol. Sci.*, 27 : 3079-3086.
- [25] Kalia P et al. 2016. Studies on the therapeutic effect of propolis along with standard antibacterial drug in *Salmonella enterica* serovar typhimurium infected BALB/c mice. *BMC Complementary Altern. Med.*, 16 : 485.
- [26] Przybyłek I & Karpinski TM. 2019. Antibacterial properties of propolis. *Molecules*, 24 : 2047.
- [27] Davies D. 2003. Understanding biofilm resistance to antibacterial agents. *Nat. Rev. Drug Discov.*, 2 : 114-122.
- [28] Hancock REW et al. 2021. Antibiofilm activity of host defence peptides: complexity provides opportunities. *Nat. Rev. Microbiol.*, 19 : 786-797.
- [29] Galié S et al. 2018. Biofilms in the food industry: health aspects and control methods. *Front. Microbiol.*, 9 : 898.
- [30] Niño-Padilla EI et al. 2021. Mycobacterial biofilms as players in human infections: a review. *Biofouling*, 37 : 410-432.
- [31] Sforzin JM. 2016. Biological properties and therapeutic applications of propolis: properties and applications of propolis. *Phytother. Res.*, 30 : 894-905.
- [32] Magnavacca A et al. 2022. The antiviral and immunomodulatory activities of propolis: an update and future perspectives for respiratory diseases. *Med. Res. Rev.*, 42 : 897-945.
- [33] Bueno-Silva B et al. 2015. Brazilian red propolis attenuates inflammatory signaling cascade in LPS-activated macrophages. *PLoS One*, 10(12), e0144954.
- [34] Bueno-Silva B et al. 2017. Brazilian red propolis effects on peritoneal macrophage activity: nitric oxide, cell viability, pro-inflammatory cytokines and gene expression. *J. Ethnopharmacol.*, 207 : 100-107.
- [35] Bueno-Silva B et al. 2020. Vestitol drives LPS-activated macrophages into M2 phenotype through modulation of NF-KB pathway. *Int. Immunopharmacol.*, 82 : 106329.
- [36] Lesmana R et al. 2024. Propolis as an autophagy modulator in relation to its roles in redox balance and inflammation regulation. *Biomed Pharmacother.*, 175 : 116745.
- [37] Huang TT et al. 2024. Novel therapeutic regimens against *Helicobacter pylori*: An updated systematic review. *Front. Microbiol.*, 15 : 1418129.
- [38] Megraud F et al. 2021. *Helicobacter pylori* resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. *Gut*, 70 : 1815-1822.
- [39] De Brito BB et al. 2019. Pathogenesis and clinical management of *Helicobacter pylori* gastric infection. *World J. Gastroenterol.*, 25 : 5578-5589.
- [40] Suzuki S et al. 2022. The Ideal *Helicobacter pylori* Treatment for the Present and the Future. *Digestion*, 103 : 62-68.
- [41] Tacconelli E et al. 2018. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.*, 18 : 318-327.
- [42] Camargo C.M et al. 2014. The Problem of *Helicobacter pylori* Resistance to Antibiotics: A Systematic Review in Latin America. *Am. J. Gastroenterol.*, 109 : 485-495.
- [43] Nie H et al. 2025. Potential Efficacy of Propolis in Treating *Helicobacter pylori* Infection and Its Mechanisms of Action. *Nutrients*, 17 : 2803.
- [44] Ding Q et al. 2021. Chinese Propolis: Ultrasound-assisted enhanced ethanolic extraction, volatile components analysis, antioxidant and antibacterial activity comparison. *Food Sci. Nutr.*, 9 : 313-330.
- [45] Holetz FB et al. 2002. Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. *Mem. Inst. Oswaldo Cruz.*, 97 : 1027-1031.



- [46] Boeing T et al. 2021. The gastroprotective effect of red propolis extract from Northeastern Brazil and the role of its isolated compounds. *J. Ethnopharmacol*, 267 : 113623.
- [47] Boeing T et al. 2021. The gastroprotective effect of red propolis extract from Northeastern Brazil and the role of its isolated compounds. *Journal of Ethnopharmacology*, 267 : 113623
- [48] Cheng YT et al. 2017. Phytochemicals enhance antioxidant enzyme expression to protect against NSAID-induced oxidative damage of the gastrointestinal mucosa. *Mol. Nutr. Food Res*. 61
- [49] Baltas N et al. 2016. Effect of propolis in gastric disorders: Inhibition studies on the growth of *Helicobacter pylori* and production of its urease. *J. Enzym. Inhib. Med. Chem.*, 31 : 46-50.
- [50] Mendonça MAA et al. 2020. Red Propolis and Its Dyslipidemic Regulator Formononetin: Evaluation of Antioxidant Activity and Gastroprotective Effects in Rat Model of Gastric Ulcer. *Nutrients*, 12 : 2951.
- [51] Zhang J & Li Z. 2015. Determination of Baicalin and Galangin Content in Propolis Tablets by High Performance Liquid Chromatography. *Tradit. Chin. Med. Res.*, 28 : 70-72.
- [52] Santiago MB et al. 2024. The Antibacterial Potential of Brazilian Red Propolis against the Formation and Eradication of Biofilm of *Helicobacter pylori*. *Antibiotics*, 13(8) : 719.
- [53] Baltas N et al. 2016. Inhibition properties of propolis extracts to some clinically important enzymes. *J. Enzym. Inhib. Med. Chem.*, 31 : 52-55.
- [54] Santiago, KB et al. 2016. Immunomodulatory/anti-inflammatory effects of a propolis-containing mouthwash on human monocytes. *FEMS Pathog. Dis.*, 74 : ftw081.
- [55] Santiago KB et al. 2018. Microbiological control and antibacterial action of a propolis-containing mouthwash and control of dental plaque in humans. *Nat. Prod. Res.*, 32 : 1441-1445.
- [56] Zuhendri F et al. 2021. The use of propolis in dentistry, oral health, and medicine : A review. *J. Oral Biosci.*, 63 : 23-34.
- [57] Mkrtchyan Z. 2011. Methods and means of *Helicobacter pylori* eradication in the oral cavity. *NewArmen.Med.J.*, 5 : 41-45.
- [58] Santiago MB et al. 2022. Brazilian red propolis presents promising anti-*H. pylori* activity in in vitro and in vivo assays with the ability to modulate the immune response. *Molecules*, 27 : 7310.
- [59] Sheen E & Triadafilopoulos G. 2011. Adverse effects of long-term proton pump inhibitor therapy. *Dig. Dis. Sci.*, 56 : 931-950.
- [60] Ripari N et al. 2025. Brazilian red propolis synergistically with imipenem modulates immunological parameters and the bactericidal activity of human monocytes against methicillin-resistant *Staphylococcus aureus* (MRSA). *J Pharm Pharmacol.*, 77(4) : 524-531.
- [61] Ripari N et al. 2023. Brazilian red propolis in combination with β -lactams exerts an efficient antibacterial action over methicillin-resistant *Staphylococcus aureus* (MRSA) strains. *J Appl Microbiol.*, 134(2) : lxac080.
- [62] Silva FRG et al. 2019. Phytochemical screening and in vitro antibacterial, antifungal, antioxidant and antitumor activities of the red propolis Alagoas. *Braz J Biol.*, 79(3) : 452-459.
- 63- Siqueira ABS et al. 2015. Antifungal activity of propolis against *Candida* species isolated from cases of chronic periodontitis. *Braz Oral Res.*, 29(1) : 1-6.
- [64] Trusheva B et al. 2006. Bioactive constituents of Brazilian red propolis. *Evid Based Complement Alternat Med.*, 3(2) : 249-54.
- [65] Siqueira AB et al. 2009. Trichophyton species susceptibility to green and red propolis from Brazil. *Lett Appl Microbiol.*, 48(1) : 90-96.
- [66] Pfaller M. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. *Am J Med*, 125 : S3-S13.
- [67] Huang M & Kao KC. 2012. Population dynamics and the evolution of antifungal drug resistance in *Candida albicans*. *FEMS Microbiol Lett.*, 333 : 85-93.
- [68] Marr KA et al. 2001. Inducible azole resistance associated with a heterogeneous phenotype in *Candida albicans*. *Antimicrob Agents Chemother*, 45 : 52-59.
- [69] Borst A et al. 2005. Rapid acquisition of stable azole resistance by *Candida glabrata* isolates obtained before the clinical introduction of fluconazole. *Antimicrob Agents Chemother*, 49 : 783-787.
- [70] Takaisi-Kikuni NB & Schilcher H. 1994. Electron microscopic and microcalorimetric investigations of the possible mechanism of the antibacterial action of a defined propolis provenance. *Planta Med.*, 60(3):222-7.
- [71] Santos LA et al. 2021. Brazilian Red Propolis shows antifungal and immunomodulatory activities against *Paracoccidioides brasiliensis*. *J Ethnopharmacol.*, 277 : 114181.
- [72] Poole CL & James SH. 2018. Antiviral Therapies for Herpes viruses: Current Agents and New Directions. *Clin Ther.*, 40 :1282-1298.
- [73] Van De Sand L et al. 2021. Antiviral Active Compounds Derived from Natural Sources against Herpes Simplex Viruses. *Viruses*, 13 : 1386.
- [74] Negri G et al. 2024. Antiviral Activity of Red Propolis Against Herpes Simplex Virus-1. *Braz. J. Pharm. Sci.*, 60 : e23746
- [75] Yosri N et al. 2021. Anti-Viral and Immunomodulatory Properties of Propolis: Chemical Diversity, Pharmacological Properties, Preclinical and Clinical Applications, and In Silico Potential against SARS-CoV-2. *Foods*, 10 : 1776.
- [76] Silva NBS et al. 2022. Potential in vitro anti-periodontopathogenic, anti-Chikungunya activities and in vivo toxicity of Brazilian red propolis. *Sci Rep.*, 12 : 21165.
- [77] Alkhalefa N et al. 2022. In vitro investigation of the antiviral activity of propolis and chitosan nanoparticles against the genotype VII Newcastle disease virus. *Front Vet Sci.*, 9 : 947641.
- [78] Justino IA et al. 2024. Antimicrobial, Antioxidant, and Anticancer Effects of Nanoencapsulated Brazilian Red Propolis Extract: Applications in Cancer Therapy. *Processes*, 12(12) : 2856. <https://doi.org/10.3390/pr12122856>
- [79] Silva NBS et al. 2024. Brazilian red propolis reduces the adhesion of oral biofilm cells and the *Toxoplasma gondii* intracellular proliferation. *Biomed Pharmacother.*, 181 : 117627.
- [80] Alanazi S & Alenzi ND. 2024. Evaluation of the antitrypanosomal activity, cytotoxicity and phytochemistry of red Brazilian propolis. *PLoS One*, 19(11) : e0313987.
- [81] Sousa LR et al. 2023. Anti-Trypanosoma cruzi Potential of Vestitol Isolated from Lyophilized Red Propolis. *Molecules*, 28(23) : 7812.